Elevance Health stock weighs a raised EPS outlook
Published on 09/28/2026 at 11:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Elevance Health stock was last at USD 396.09 on the NYSE on September 25, 2026, down 0.54 percent from the prior close. The company is carrying a raised 2026 adjusted earnings outlook of at least USD 27.00 per share after a stronger second quarter.
Guidance moves above consensus
According to MarketBeat on September 19, 2026, Elevance Health set full-year adjusted EPS guidance at USD 27.00, compared with analyst consensus of USD 27.16. The same report said second quarter EPS reached USD 7.45 against consensus of USD 6.21, a USD 1.24 beat.
The guidance figure is adjusted rather than GAAP. That distinction matters because the company also continues to disclose reported earnings of at least USD 20.10 per diluted share for 2026, including identified unfavorable items, according to a September filing summarized by StockTitan.
Revenue grows while membership shifts
In the Q2 2026 earnings call, Fortune reported operating revenue of USD 49.8 billion, up 0.8 percent year over year, and 44.9 million medical members at June 30, 2026. The company also reported USD 1.9 billion in second quarter operating cash flow.
The operating picture is mixed in composition. Elevance Health said Medicare Advantage performance improved after portfolio actions, while Medicaid remained pressured by elevated utilization and a second quarter operating margin outlook of negative 1.75 percent, as described in the earnings call transcript.
Stock remains below yearly high
At USD 396.09, the stock stood 9.20 percent below its 52-week high of USD 436.24 and above its 52-week low of USD 274.84 on September 25, 2026. Market capitalization was USD 85.9 billion and trading volume was 1,169,701 shares for that snapshot.
For investors, the central test is whether the improved Medicare Advantage performance and Carelon expansion can offset Medicaid cost pressure. The company has also pointed to at least 12 percent adjusted EPS growth in 2027, but that outlook remains tied to execution across several businesses rather than one recovery driver.
Elevance Health stock keeps guidance in view
Elevance Health stock was last at USD 396.09 on the NYSE on September 25, 2026. The valuation now reflects a company balancing a higher 2026 adjusted EPS floor against persistent medical-cost and Medicaid risks.
Elevance Health stock data
- Company: Elevance Health Inc.
- ISIN: US2855211023
- Ticker: ELV
- Trading venue: NYSE
- Price (as of September 25, 2026, 4:00 p.m. ET): USD 396.09
- Market capitalization: USD 85.9 billion (as of September 25, 2026)
- 52-week range: USD 274.84-436.24 (as of September 25, 2026)
- Sector / Industry: Healthcare / Medical Healthcare Plans
